Your browser doesn't support javascript.
loading
Effects of Gadolinium Deposition in the Brain on Motor or Behavioral Function: A Mouse Model.
Akai, Hiroyuki; Miyagawa, Kazuya; Takahashi, Kohei; Mochida-Saito, Atsumi; Kurokawa, Kazuhiro; Takeda, Hiroshi; Tsuji, Minoru; Sugawara, Haruto; Yasaka, Koichiro; Kunimatsu, Akira; Inoue, Yusuke; Abe, Osamu; Ohtomo, Kuni; Kiryu, Shigeru.
Afiliação
  • Akai H; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Miyagawa K; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Takahashi K; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Mochida-Saito A; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Kurokawa K; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Takeda H; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Tsuji M; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Sugawara H; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Yasaka K; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Kunimatsu A; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Inoue Y; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Abe O; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Ohtomo K; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
  • Kiryu S; From the Department of Radiology, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan (H.A., H.S., K.Y., A.K.); Department of Pharmacology, and School of Pharmacy (K.M., K.T., A.M.S., K.K., M.T.), and International University of Health and Welfare
Radiology ; 301(2): 409-416, 2021 11.
Article em En | MEDLINE | ID: mdl-34463554
ABSTRACT
Background Recent studies showing gadolinium deposition in multiple organs have raised concerns about the safety of gadolinium-based contrast agents (GBCAs). Purpose To explore whether gadolinium deposition in brain structures will cause any motor or behavioral alterations. Materials and Methods This study was performed from July 2019 to December 2020. Groups of 17 female BALB/c mice were each repeatedly injected with phosphate-buffered saline (control group, group A), a macrocyclic GBCA (group B), or a linear GBCA (group C) for 8 weeks (5 mmol per kilogram of bodyweight per week for GBCAs). Brain MRI studies were performed every other week to observe the signal intensity change caused by the gadolinium deposition. After the injection period, rotarod performance test, open field test, elevated plus-maze test, light-dark anxiety test, locomotor activity assessment test, passive avoidance memory test, Y-maze test, and forced swimming test were performed to assess the locomotor abilities, anxiety level, and memory. Among-group differences were compared by using one-way or two-way factorial analysis of variance with Tukey post hoc testing or Dunnett post hoc testing. Results Gadolinium deposition in the bilateral deep cerebellar nuclei was confirmed with MRI only in mice injected with a linear GBCA. At 8 weeks, contrast ratio of group C (0.11; 95% CI 0.10, 0.12) was higher than that of group A (-2.1 × 10-3; 95% CI -0.011, 7.5 × 10-3; P < .001) and group B (2.7 × 10-4; 95% CI -8.2 × 10-3, 8.7 × 10-3; P < .001). Behavioral analyses showed that locomotor abilities, anxiety level, and long-term or short-term memory were not different in mice injected with linear or macrocyclic GBCAs. Conclusion No motor or behavioral alterations were observed in mice with brain gadolinium deposition. Also, the findings support the safety of macrocyclic gadolinium-based contrast agents. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Chen in this issue.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Comportamento Animal / Encéfalo / Meios de Contraste / Gadolínio / Atividade Motora Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Comportamento Animal / Encéfalo / Meios de Contraste / Gadolínio / Atividade Motora Idioma: En Ano de publicação: 2021 Tipo de documento: Article